Technical Analysis for NITE - Nightstar Therapeutics plc

Grade Last Price % Change Price Change
grade B 13.96 9.06% 1.16
NITE closed up 9.06 percent on Thursday, January 17, 2019, on 39 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical NITE trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 50 DMA Bullish 0.00%
Jan 17 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 17 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Jan 17 Upper Bollinger Band Touch Strength 0.00%
Jan 16 Fell Below 50 DMA Bearish 9.06%
Jan 16 180 Bearish Setup Bearish Swing Setup 9.06%
Jan 15 Crossed Above 50 DMA Bullish 5.36%
Jan 15 180 Bullish Setup Bullish Swing Setup 5.36%
Jan 15 Upper Bollinger Band Walk Strength 5.36%
Jan 15 Inside Day Range Contraction 5.36%

Older signals for NITE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Nightstar Therapeutics Limited is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Is NITE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.545
52 Week Low 9.59
Average Volume 118,506
200-Day Moving Average 15.8785
50-Day Moving Average 12.996
20-Day Moving Average 12.5105
10-Day Moving Average 13.218
Average True Range 1.1164
ADX 16.44
+DI 21.6542
-DI 14.6411
Chandelier Exit (Long, 3 ATRs ) 11.1208
Chandelier Exit (Short, 3 ATRs ) 13.7092
Upper Bollinger Band 14.1874
Lower Bollinger Band 10.8336
Percent B (%b) 0.93
BandWidth 26.807881
MACD Line 0.1664
MACD Signal Line -0.0153
MACD Histogram 0.1817
Fundamentals Value
Market Cap 392.29 Million
Num Shares 28.1 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -21.48
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.11
Resistance 3 (R3) 15.96 15.11 15.75
Resistance 2 (R2) 15.11 14.56 15.18 15.63
Resistance 1 (R1) 14.53 14.22 14.82 14.68 15.51
Pivot Point 13.68 13.68 13.82 13.75 13.68
Support 1 (S1) 13.10 13.13 13.39 13.25 12.41
Support 2 (S2) 12.25 12.79 12.32 12.29
Support 3 (S3) 11.67 12.25 12.17
Support 4 (S4) 11.82